Symposium: Accelerating the development of cabamiquine-pyronaridine for malaria chemoprevention in Africa
When: Thursday 25 April 2024, 10:30-12:00 (CAT)|
Where: Kigali Convention Centre, Room AD11
Organiser: Merck (Germany)
Chemoprevention is an important tool for malaria control in children and pregnant women. However, few drugs are available for use in this space and even fewer molecules are in development for this indication. Drugs for chemoprevention such as sulfadoxine-pyrimethamine face decreasing effectiveness due to drug resistance, poor coverage and adherence. Cabamiquine, a new antimalarial compound is being developed in combination with pyronaridine for chemoprevention with single dose potential, reasonably long post-treatment protection and suitable for pregnant women. The conventional pathways for bringing health intervention to patients have been successfully challenged during the COVID-19 pandemic with fast-track development and approval of vaccines. This precedent offered new opportunities to bring drugs and other therapeutics faster to patients.
This symposium will present new scientific knowledge on innovative approaches for accelerated drug development as well as data de-risking drug resistance and its use in pregnant women. It will also highlight models to de-risk clinical development of drugs for use in pregnancy.
EDCTP project(s) highlighted
Agenda
Chairs
- Jean Louis Ndiaye, Université Thies (Sénégal)
- Christine Manyando, Tropical Diseases Research Centre (TDRC, Zambia)
In-silico platforms for development and reproductive toxicity studies to support the use of cabamiquine in pregnancy
Claudia Demarta-Gatsi, Merck Global Health Institute (Merck KGaA, Switzerland)
Evaluating the propensity of selecting mutant parasites and rationalizing the partner-drug selection for cabamiquine using real-world parasites studies
Laurent Dembele, Université des Sciences, des Techniques et des Technologies de Bamako (Mali)
Model-informed drug development to support registration for cabamiquine-pyronaridine
Lucy Okell, Imperial College (UK)
Adaptive study designs and the use of synthetic data in clinical trials on malaria
Joseph Okebe, Merck KGaA (Switzerland)